Role of treg cells and TGF-β1 in patients with systemic lupus erythematosus: A possible relation with lupus nephritis

Immunological Investigations

Volumn 41, Issue 1, 2012, Pages 15-27

  Xing, Qian ^a   Su, Houheng ^a   Cui, Jiajia ^a   Wang, Bin ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Lupus nephritis; Regulatory T cells; SLE; TGF 1

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE LEVEL;

ADULT; ANTIGENS, CD4; BIOLOGICAL MARKERS; CELL COUNT; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 81555212323     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.578189     Document Type: Article

References (32)

1. Aoki, C. A., Borchers, A. T., Li M., Flavell, R. A., Bowlus, C. L., Ansari, A. A., Gershwin, M. E. (2005). Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun. Rev. 4(7):450-9.
2. Azhar, M., Yin,M., Bommireddy, R., Duffy, J. J., Yang, J., Pawlowski, S. A., Boivin, G. P., Engle, S. J., Sanford, L. P., Grisham, C., Sing, H. R. R., Babcock, G. F., Doetschman, T. (2009). Generation of mice with a conditional allele for transforming growth factor beta 1 gene. Genesis 47(6):423-31.
3. 4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 40(7):521-8.
4. Becker-Merok, A., Eilertsen, G. O., Nossent, J. C. (2010). Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 37(10):2039-45.
5. Bonelli, M., Savitskaya, A., von Dalwigk, K., Steiner, C. W., Aletaha, D., Smolen, J. S.Scheinecker C. (2008). Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int. Immunol. 20(7):861-8.
6. DeMuro, P., Faedda, R., Fresu, P., Masala, A., Cigni, A., Concas, G.,Mela, M. G., Satta, A., Carcassi, A., Sanna, G. M., Cherchi, G. M. (2004). Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol. Res. 49(3):293-8.
7. Fahlen, L., Read, S., Gorelik, L., Hurst, S. D., Coffman, R. L., Flavell, R. A., Powrie, F. (2005). T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 201(5):737-46.
8. Gagliardini, E., Benigni, A. (2006). Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev. 17(1-2):89-96.
9. Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., Rudensky, A. Y. (2007). Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445(7129):771-5.
10. Heinlen, L. D., McClain, M. T., Merrill, J., Akbarali, Y. W., Edgerton, C. C., Harley, J. B., James, J. A. (2007). Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum, 56(7):2344-51.
11. Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40(9):1725.
12. Kaplan, J., Woodworth, L., Smith, K., Coco, J., Vitsky, A., McPherson, J. (2008). Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-beta1 in the MRL/lpr lupus mouse model. Lupus 17(9):822-31.
13. La Cava, A., Fang, C. J., Singh, R. P., Ebling, F., Hahn, B. H. (2005). Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev. 4(8):515-9.
14. 4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 601:113-9.
15. Maloy, K. J., Powrie, F. (2001). Regulatory T cells in the control of immune pathology. Nat. Immunol. 2(9):816-22.
16. 4+CD25+ regulatory T cells. J. Exp. Med. 201(7):1061-7.
17. Murakami, K., Takemura, T., Hino, S., Yoshioka, K. (1997). Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr. Nephrol. 11(3):334-6.
18. Nakamura, K., Kitani, A., Strober, W. (2001). Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194(5):629-44.
19. Ohtsuka, K., Gray, J. D., Stimmler, M. M., Horwitz, D. A. (1999). The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 8(2):90-4.
20. Ruiz-Arguelles, A., Alarcon-Segovia, D., Llorente, L., Del Giudice-Knipping, J. A. (1980). Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus. Arthritis Rheum. 23(9):1004-9.
21. 4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4):345-52.
22. 4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32.
23. Sfikakis, P. P., Souliotis, V. L., Fragiadaki, K. G., Moutsopoulos, H. M., Boletis, J. N., Theofilopoulos, A. N. (2007). Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123(1):66-73.
24. 4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann. Rheum. Dis. 65(11):1512-7.
25. Wan, Y. Y., Flavell, R. A. (2007). Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445(7129):766-70.
26. 4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13(3):192-200.
27. 4+ regulatory T cells. Int. Immunol. 16(11):1643-56.
28. 4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin. Exp. Immunol. 153(2):182-7.
29. 4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann. Rheum. Dis. 67(7):1037-40.
30. Zheng, S. G. (2010). Transforming growth factor-beta level: indicator for severity of disease and organ damage in patients with systemic lupus erythematosus. J. Rheumatol. 37(10):1983-5.
31. 4+CD25- precursors. J. Immunol. 169(8):4183-9.
32. 4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178(4):2018-27.